Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Misty Shields

Thoracic Oncology · IUSM

View

Dr. Gilberto Lopes

Thoracic Oncology · University of Miami

View

Dr. Jacob Sands

Thoracic Oncology · Dana-Farber Cancer Institute

View

Dr. Kathleen Cooney

GU Oncology · Duke

View

Dr. Rebecca Shatsky

Breast Oncology · UCSD

View

Dr. Robert Bast

Breast Oncology · MD Anderson Cancer Center

View

Dr. Julia Close

General Oncology · UF

View

Dr. Sara Tolaney

Breast Oncology · Dana-Farber Cancer Institute

View

Dr. Allison Fitzgerald

General Oncology · Dana-Farber Cancer Institute

View

Dr. Jason Mouabbi

Breast Oncology · MD Anderson Cancer Center

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    RS

    Dr. Rafael Santana Davila

    Medical Oncology · Thoracic Oncology
    Swedish Medical Center
    rafaels

    Research

    Dual PD-1 and CTLA4 Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Advanced Salivary Gland Cancers

    2025

    Via Head & Neck

    Research

    Napsin A-specific T-cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer

    2025

    Via Journal for Immunotherapy of Cancer

    Research

    Osimertinib retreatment for patients with advanced EGFR-mutated non-small cell lung cancer

    2025

    Via Cancer Treatment and Research Communications

    Research

    Molecular phenotyping of small cell lung cancer using targeted cfDNA profiling of transcriptional regulatory regions

    2024

    Via Science Advances

    Research

    A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer

    2024

    Via Clinical Cancer Research

    Research

    A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)

    2024

    Via Journal of Clinical Oncology

    Research

    Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients

    2022

    Via Cancer Medicine

    Research

    Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer

    2022

    Via Advances in Radiation Oncology

    Research

    Chemo and Immuno-Therapeutic Options for Nonsmall Cell Lung Cancer Lung Cancer

    2022

    Via The Surgical Clinics of North America

    Research

    A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy

    2021

    Via Cancer Treatment and Research Communications

    Research

    Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non-Small Cell Lung Cancer: The NRG-LU001 Phase 2 Randomized Clinical Trial

    2021

    Via JAMA Oncology

    Research

    Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

    2021

    Via Nature Medicine

    Research

    Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study

    2021

    Via The Lancet Oncology

    Research

    High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors

    2021

    Via Journal of Palliative Medicine

    Research

    Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

    2021

    Via Journal of the National Comprehensive Cancer Network